Amgen-JPM-20240108.pdf

1、ROBERT A.BRADWAY,CHAIRMAN AND CHIEF EXECUTIVE OFFICER42ND ANNUAL J.P.MORGAN HEALTHCARE CONFERENCEJanuary 8,20242Provided January 8,2024,as part of an oral presentation and is qualified by such,contains forward-looking statements,actual results may vary materially;Amgen disclaims any duty to update.T

2、his presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen.All statements,other than statements of historical fact,are statements that couldbe deemed forward-looking statements,including any statements on the outcome,benefits and synergies of

3、 collaborations,or potential collaborations,with any other company(including BeiGene,Ltd.or Kyowa Kirin Co.,Ltd.),the performance of Otezla(apremilast)(including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion),our acquisitions of Teneobio,Inc.,ChemoCentryx,Inc.,or Horizon T

4、herapeutics plc(including the prospective performance and outlook of Horizons business,performance and opportunities,any potential strategic benefits,synergies oropportunities expected as a result of such acquisition,and any projected impacts from the Horizon acquisition on our acquisition-related e

5、xpenses going forward),as well as estimates of revenues,operating margins,capital expenditures,cash,other financial metrics,expected legal,arbitration,political,regulatory or clinical results or practices,customer and prescriber patterns or practices,reimbursement activities and outcomes,effects of

6、pandemics or other widespread health problems on our business,outcomes,progress,and other such estimates and results.Forward-lookingstatements involve significant risks and uncertainties,including those discussed below and more fully described in the Securities and Exchange Commission reports filed